Table 1.
Treatment | Models | Macrophage autophagy | Type of macrophage | Outcome | In vitro or in vivo | References |
---|---|---|---|---|---|---|
CS | – | AM autophagy↑ | AMs | CS-induced PF↓ | In vivo | (79) |
Trehalose | – | AM autophagy↑ | AMs | CS-induced PF↓ | In vivo and in vitro | (80, 81) |
Dioscin | – | AM autophagy↑ | AMs | CS-induced PF↓ | In vivo | (79, 82) |
Dioscin | (Atg5flox/floxDppa3-Cre/+) mice | AM autophagy↓ | AMs | CS-induced PF↑ | In vivo | (79) |
MicroRNA-205-5p | – | AM autophagy↑ | AMs | CS-induced PF↓ | In vivo and in vitro | (83) |
CS | (Atg5fl/flLysM-Cre+) mice | Monocyte-derived macrophage autophagy↓ | Monocyte-derived macrophages | CS-induced PF↑ | In vivo | (84) |
SARS-CoV-2- | – | – | CD163+ monocyte-derived macrophages↑ | SARS-CoV-2-induced PF↑ | Patients | (85) |
Viral and bacterial | Deficiency of TRIM29 | Unknown | AMs↓ | Type I interferons↑, less susceptible to the influenza virus | In vivo | (87) |
Macrophage depletion | I/R | – | Macrophages↓ | Renal fibrosis↓ | In vivo | (95, 96) |
High-fat diet feeding and treated with low-dose lipopolysaccharide | (Atg5fl/flLysM-Cre+) mice | Macrophage autophagy↓ | proinflammatory M1↑, anti-inflammatory M2↓ | Inflammation↑ | In vivo | (21) |
USP19 | – | Macrophage autophagy↑ | Anti-inflammatory M2↑ | Inflammation↓ | In vivo | (24) |
– | UUO mouse model | Macrophage mitophagy↑ | Macrophage M1 polarization↓ | Inflammation, renal fibrosis↓ | In vivo | (100) |
Rapamycin | – | Macrophage autophagy↑ | Macrophage M1 polarization↓ | Renal fibrosis↓ | In vivo and in vitro | (102) |
Quercetin | Obstructive mouse model | – | Macrophage M1 polarization↓ | Renal fibrosis↓ | In vivo | (103) |
Repeated intraperitoneal injection of carbon tetrachloride | Specifically knock out the Atg5 in the myeloid lineage | Macrophage autophagy↓ | – | Liver injury, chronic liver inflammation, and liver fibrosis↑ | In vivo | (108) |
Pharmacological and gene-level interventions to inhibit LAP | – | – | Controlling polarization of macrophages | liver inflammation, and liver fibrosis↑ | In vivo | (113) |
– | Myocardial infarction | – | CCR2+ macrophages | Cardiac fibrosis and heart failure | In vivo | (127) |
Inhibition of TLR2 | – | – | Macrophages↓ | Ang II-induced cardiac fibrosis↓, inflammatory response↓ | In vivo | (135) |
Adiponectin | – | Macrophage autophagy↑ | – | Ang II-induced cardiac fibrosis↓, inflammatory response↓ | In vivo and in vitro | (136) |
AM: alveolar macrophage; CS: crystalline silica; PF: pulmonary fibrosis; UUO: unilateral ureteral obstruction; I/R: ischemia/reperfusion; USP19: ubiquitin-specific protease 19; LAP: LC3-associated phagocytosis; CCR2-: C-C chemokine receptor type 2 negative; CCR2+: C-C chemokine receptor type 2 positive.
↑ means this biological process is activated.
↓ means this biological process is suppressed.